Pneumococcal Pneumonia Vaccine Research Study
Researchers at the University of Alabama at Birmingham are conducting a study to compare an updated pneumococcal pneumonia vaccine to the existing vaccine.
Fast Facts
Generally healthy (no significant neurological diseases or medical illnesses)
2-17 Years Old
No Vaccines in the Last 4 Weeks Other Than Flu
Compensation Provided
Conducted in Birmingham, AL
Study Background
Researchers at the University of Alabama at Birmingham are conducting a study to compare the use of an updated pneumococcal pneumonia vaccine to the older version of the vaccine for youth and children.
Study Background
Researchers at the University of Alabama at Birmingham are conducting a study to compare the use of an updated pneumococcal pneumonia vaccine to the older version of the vaccine for youth and children.
Pneumococcal disease is known to be dangerous for children under five years old, and vaccination remains a crucial preventive measure. There are more than 100 pneumococcal variants, which requires the need for a more robust and durable vaccine protection.
Our study team aims to understand the safety and efficacy of an updated vaccine when compared to the existing Prevnar 20 vaccine. Half of participants will receive the updated vaccine and half the participants will receive the existing vaccine. The study is double blinded, which means both the study team and the families participating will not know which vaccine the child received.
Join our study today to help the study of an updated pnuemococcal pneumonia vaccine!
Additional Information
The study is designed to collect data about the safety and efficacy of the experimental vaccine for infants, toddlers, children, and adolescents.
You or your child may qualify for a study if the following criteria are met:
Inclusion Criteria:
- Ages 2-17
- Generally healthy (no significant neurological diseases or medical illnesses)
Exclusion Criteria:
Received a vaccine in the last 4 weeks (other than the flu vaccine)
Ever received the pneumococcal pneumonia vaccine
Pregnant or breastfeeding
If a participant is enrolled in this study, they/their legal guardian will be asked to sign the consent form. The participant will then be randomized to receive either PCV21 (the new vaccine) or Prevnar 20 (the existing vaccine).
There are 2 in-person visits and 2 telephone calls over a period of 6 months. The participant/legal guardian will be asked to keep a study diary.
Study procedures include a physical examination, blood samples, pregnancy test (if applicable), receiving the study vaccine, a targeted medical exam for post-vaccine symptoms, and diary training and review.
Participant compensation is $100.00 for each in-person visit, $35.00 for each telephone visit, and $20.00 weekly for completion of study diary, for a total of up to $790.00.
There is no cost for you to participate in our research study.